DFTX — Definium Therapeutics, Inc.
—
Nasdaq ·
Materials ·
Chemicals ·
CIK 1813814 ·
Last close
$22.88
Market Cap
$2.50B
52W High
$26.25
52W Low
$16.55
ADV30
1,792,578
Next earnings
2026-07-30
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -59,220,000 | -77,098,000 | 401,293,000 | 262,518,000 | 122,444,000 |
| Dec 2025 | 0 | — | -47,578,000 | -50,436,000 | 440,100,000 | 257,837,000 | 107,773,000 |
| Sep 2025 | 0 | — | -45,669,000 | -67,265,000 | 236,916,000 | 19,959,000 | 106,320,000 |
| Jun 2025 | 0 | — | -40,903,000 | -42,744,000 | 265,091,000 | 33,392,000 | 79,691,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-131,560,000
Investing CF
$-151,606,000
Financing CF
$267,269,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.04
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-582,672,000
Inventory
—
Receivables
—
ST Investments
$153,756,000
EBIT TTM
$-178,311,000
Pretax Income TTM
$-183,793,000
Interest Exp TTM
$5,482,000
Analysts
15
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -166,309,000 | -183,793,000 | 440,100,000 | 107,773,000 | — | -131,560,000 |
| Dec 2024 | 0 | -103,916,000 | -108,679,000 | 302,151,000 | 60,703,000 | — | -79,129,000 |
| Dec 2023 | 0 | -93,866,000 | -95,732,000 | 124,541,000 | 46,407,000 | — | -64,365,000 |
| Dec 2022 | 0 | -66,331,000 | -56,796,000 | 169,993,000 | 19,076,000 | — | -50,139,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.58
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ROG | ROGERS CORP | $2.57B | $144.04 | — |
| MTX | MINERALS TECHNOLOGIES INC | $2.42B | $78.11 | — |
| HUN | Huntsman CORP | $2.58B | $14.74 | — |
| NGVT | Ingevity Corp | $2.38B | $68.53 | — |
| CURLF | Curaleaf Holdings, Inc. | $2.31B | $3.31 | — |
News headlines (Yahoo Finance, 1h cache)
Definium Therapeutics Eyes Key DT-120 Depression Data, Advances Anxiety Program
2026-05-23 01:02 · Yahoo
Definium Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
2026-05-21 11:00 · Yahoo
Definium Begins Second Phase 3 DT120 Trial As Valuation Gap Widens
2026-05-21 06:10 · Yahoo
Dianthus Therapeutics Is Up 320% in a Year. One Major Investor Just Reduced Its Stake but Still Seems Bullish
2026-05-18 17:33 · Yahoo
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
2026-05-18 14:03 · Yahoo
Definium Therapeutics Announces First Patient Dosed in Ascend, the Second Phase 3 Pivotal Study of DT120 ODT in Major Depressive Disorder
2026-05-12 11:00 · Yahoo
Definium Therapeutics Announces New Employee Inducement Grants
2026-05-11 20:01 · Yahoo
Definium Therapeutics (DFTX) Deepens Losses Advancing Psychedelic Pipeline Is Its Cash Strategy Still Coherent?
2026-05-09 01:12 · Yahoo
Definium Therapeutics Q1 Earnings Call Highlights
2026-05-08 01:35 · Yahoo
Definium (DFTX) Q1 2026 Earnings Transcript
2026-05-07 22:42 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.